Associated Papers
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Sperling AS et al.
Blood, 2022
35512188 (PubMed )
Supplement: BLOOD_BLD-2021-014956-mmc1.pdf
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
Zhang H et al.
Nature Communications, 2019
30651561 (PubMed )
Supplement: 41467_2018_8263_MOESM5_ESM.xlsx › Supplementary_Data_2
Select a paper to view details